title: Three-year visual outcome of photodynamic therapy plus intravitreal bevacizumab with or without subtenon triamcinolone acetonide injections for polypoidal choroidal vasculopathy.
abstract: OBJECTIVE
  To compare the 3-year visual outcome after double therapy of photodynamic therapy (PDT) with intravitreal bevacizumab (IVB) and triple therapy of PDT combined with IVB and subtenon triamcinolone acetonide (STTA) injections for polypoidal choroidal vasculopathy (PCV).
  
  
  METHODS
  Retrospective, comparative, interventional case series.
  
  
  METHODS
  Medical records for 36 eyes in 36 patients (33 men, 3 women; mean age 73.5 years old; range 63-82 years old) with treatment-naive subfoveal PCV were reviewed retrospectively. Of the 36 eyes, 17 were treated with double therapy and 19 with triple therapy.
  
  
  RESULTS
  The change in visual acuity after triple therapy was significantly better than that after double therapy (p<0.05). At 36 months, improvement in visual acuity was seen in 5 eyes (29.4%) in the double therapy group and 10 eyes (52.6%) in the triple therapy group. Retreatment using the initial treatment was performed for six eyes (35.3%) in the double therapy group and five eyes (26.3%) in the triple therapy group, and treatment-free period was significantly longer in the triple therapy group (p<0.05). The mean number of additional antivascular endothelial growth factor therapy was higher in the double therapy group. Post-treatment vitreous haemorrhage or retinal pigment epithelium tear occurred only in the double therapy group, in one eye (5.9%) and one eye (5.9%), respectively.
  
  
  CONCLUSIONS
  Initial therapy consisting of a single session of PDT combined with IVB and STTA improves vision in treatment-naive subfoveal PCV. Compared with double therapy, this triple therapy may be more effective for PCV.
authors: Department of Ophthalmology, Jikei University School of Medicine, Tokyo, Japan.
authors: Tsutomu
authors: T
authors: Sakai
authors: Department of Ophthalmology, Jikei University School of Medicine, Tokyo, Japan.
authors: Yasuhiro
authors: Y
authors: Ohkuma
authors: Department of Ophthalmology, Jikei University School of Medicine, Tokyo, Japan.
authors: Hideo
authors: H
authors: Kohno
authors: Department of Ophthalmology, Jikei University School of Medicine, Tokyo, Japan.
authors: Takaaki
authors: T
authors: Hayashi
authors: Department of Ophthalmology, Jikei University School of Medicine, Tokyo, Japan.
authors: Akira
authors: A
authors: Watanabe
authors: Department of Ophthalmology, Jikei University School of Medicine, Tokyo, Japan.
authors: Hiroshi
authors: H
authors: Tsuneoka
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000503:physiopathology; D004396:Coloring Agents; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007208:Indocyanine Green; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy; D011127:Polyps / Q000188:drug therapy* / Q000503:physiopathology; D012189:Retrospective Studies; D058475:Tenon Capsule / Q000187:drug effects; D041623:Tomography, Optical Coherence; D014222:Triamcinolone Acetonide / Q000627:therapeutic use*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D004396:Coloring Agents; D005938:Glucocorticoids; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D014222:Triamcinolone Acetonide; D007208:Indocyanine Green
keywords: Treatment Medical